Waters Corp completes merger with BD's Biosciences business
Waters Corporation's stock fell 13.71% as it crossed below the 5-day SMA amid broader market declines, with the Nasdaq-100 down 0.34% and the S&P 500 down 0.17%.
The company has successfully completed its merger with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses, establishing a global leader in life sciences and diagnostics. This merger is expected to drive expansion in high-growth markets, with Dr. Claire M. Fraser appointed to the Waters Board to support future growth. The merger also resulted in the establishment of four new divisions focused on high-volume testing and adjacent markets, enhancing Waters' competitiveness.
The implications of this merger are significant, as it positions Waters Corporation to leverage its new capabilities and market presence. The company aims to capitalize on growth opportunities in pharmaceuticals and diagnostics, which could lead to increased revenue and market share in the coming years.
Trade with 70% Backtested Accuracy
Analyst Views on WAT
About WAT
About the author

- Sales Performance Beat: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating stable performance in a challenging economic environment despite ongoing headwinds.
- Earnings Guidance Cut: The company lowered its fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65, below the consensus of $14.72, reflecting pressures and uncertainties in future business operations.
- Analyst Rating Changes: RBC Capital Markets reduced its price target for Becton Dickinson from $210 to $172, citing FY26 as a transition year with an expected organic revenue growth of 2.5%, which may impact investor confidence moving forward.
- Market Reaction: Following the announcement, Becton Dickinson's shares fell by 17.44% to $171.23, indicating investor concerns regarding the company's growth potential, especially in light of multiple business headwinds.
- Market Sentiment: Bulls have regained control of the market following previous concerns over artificial intelligence, leading to a positive outlook for risky assets, particularly in the tech sector.
- Ongoing Rally: The rally in real assets continues as investors anticipate a series of important economic data releases in the coming days.
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
- U.S. Stock Market Performance: U.S. stock indexes experienced gains on Monday, with the overall market rising by 0.90%.
- Specific Index Movements: The S&P 500 increased by 0.47%, while the Dow Jones Industrial Average saw a slight rise of 0.04%.
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
- Software Stock Rebound: Following last week's severe selloff, the iShares Expanded Tech-Software Sector ETF (NYSE:IGV) jumped over 3% on Monday, marking its strongest daily gain since late April 2025, indicating renewed investor interest in software stocks and a potential recovery in market confidence.
- Nasdaq Outperformance: The Nasdaq 100 climbed 1%, significantly outperforming broader Wall Street, while the S&P 500 added 0.7%, suggesting that the strong rebound in tech stocks is driving overall market gains and may attract more capital inflows.
- Individual Stock Surge: AppLovin Corp. (NASDAQ:APP) surged more than 14% after logging four consecutive weekly declines, reflecting optimistic market sentiment regarding its future growth potential, which could draw more investor attention to the company.
- Commodity Market Recovery: Oil prices rose over 2% to $64.6 a barrel, while gold rebounded 2.5% to $5,090 an ounce, and silver soared over 6% to $82 an ounce, indicating an improvement in market risk appetite that may positively impact related industries.










